Early Results of Lower dose Dasatinib 50mg Daily as Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

BACKGROUND: Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor (TKI). It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Naqvi, Kiran, Jabbour, Elias, Skinner, Jeffrey, Yilmaz, Musa, Ferrajoli, Alessandra, Bose, Prithviraj, Thompson, Philip, Alvarado, Yesid, Jain, Nitin, Takahashi, Koichi, Burger, Jan, Estrov, Zeev, Borthakur, Gautam, Pemmaraju, Naveen, Paul, Shilpa, Cortes, Jorge, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6388399/
https://ncbi.nlm.nih.gov/pubmed/29723397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31357
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars